Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liatermin - MedGenesis Therapeutix

Drug Profile

Liatermin - MedGenesis Therapeutix

Alternative Names: BVF-014; GDNF; Glial-derived neutrotrophic factor; r-metHuGDNF

Latest Information Update: 30 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; MedGenesis Therapeutix
  • Class Antiparkinsonians; Biological proteins; Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • Preclinical Inborn genetic disorders; Peripheral nerve injuries
  • Discontinued Amyotrophic lateral sclerosis; Deafness; Epilepsy; Pain; Sensorineural hearing loss

Most Recent Events

  • 11 Sep 2018 Discontinued - Preclinical for Epilepsy in Canada (Parenteral)
  • 11 Sep 2018 Discontinued - Preclinical for Sensorineural hearing loss in Canada (Parenteral)
  • 11 Sep 2018 Preclinical trials in Inborn genetic disorders in Canada (Parenteral) (MedGenesis pipeline, September 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top